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Background
HIV-1 entry is a dynamic process with two main actors:
HIV-1 envelope glycoproteins: gp120 and gp41. The
entry is a key step of the infection: blockade of this step
leads to an inhibition of the viral replication. Our main
focus in this study is the key actor of the viral entry and
fusion: gp41. Our goal is to develop HIV-1 entry inhibi-
tors using two strategies: i) the development of immu-
nogens capable to induce neutralizing antibodies, ii) the
modeling and synthesize as monomeric or trimeric pep-
tide inhibitors derived from the HR1 and HR2 regions
of gp41.
Material and methods
HR1 and HR2 regions of HIV-1 gp41 were synthesized
chemically as monomeric or trimeric peptides. Punctial
D-amino acid substitutions (C34M2 and C34 M4) were
introduced at the more susceptible enzymatic cleavage
sites. These peptides were then tested for their antiviral
activity and their capacity to elicit neutralizing antibo-
dies in mice.
Results
We studied, in the first part, the complex formed by the
HR1 and HR2 domains, the purification of this complex,
its stability and its ability to induce neutralizing antibodies,
in a vaccine approach. We showed that HR1-HR2 com-
plex is rapidly formed (less than 1 min) and remained
stable as demonstrated by its inability, in contrast to each
free peptide, to inhibit syncytia formation. Purified pre-
formed HR1-HR2 complex and monomeric HR1 and HR2
peptides are immunogenic in mice and induce antibodies
that recognize total HIV-1 envelope. They neutralize
fusion when incubated at 27°C.
In a second approach trimeric synthetic peptides mod-
elling HR1 and HR2 of HIV-1 gp41 were tested for their
antiviral activities and used as immunogens in mice. The
obtained results showed that these trimers could inter-
act with the HR1 or HR2 regions and had a similar ,for
the trimerC34, and an ameliorated antiviral activity, for
the TrimerN36, compared to the monomer C34 and
N36. More interestingly we showed that antibodies pro-
duced against trimeric HR1 and HR2 or against the hex-
americ complex HR1-HR2 were able to recognize native
envelope glycoproteins gp41 and gp160 of HIV-1 and to
inhibit syncytia formation in co-culture of HeLa cells
expressing CD4-CC5R/CXCR4 receptors and HeLa cells
stably expressing gp120/gp41 from R5 or X4 tropic
viruses.
Conclusions
Our data showed that: -the introduction of punctual
D-amino acid substitutions can help to increase the sta-
bility of the peptides without altering their antiviral
activity, - HRI and HRII, modelled as trimeric peptides,
conserve their antiviral activities and are able to induce
anti-peptide antibodies which recognize native gp41 and
gp160 envelope glycoproteins and interfere with cell-cell
fusions at physiological conditions.
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